Shenzhen Fushan Biotech Co., Ltd.   Report issue

For profit Phase 3
Founded: Hangzhou China (2016)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2018
NCT03932136
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shenzhen Fushan Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

sulforaphane (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mental Disorders (Phase 3)

Psychotic Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1